Tiny study tracks experimental schizophrenia Drug's journey in healthy men

NCT ID NCT07455084

Not yet recruiting Knowledge-focused Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial will give 8 healthy men a single dose of a radioactive-labeled experimental drug called SEP-380135, which is being developed for schizophrenia. The goal is to track how the drug is absorbed, broken down, and eliminated from the body. This study does not test whether the drug works; it only gathers basic information needed for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SEP-380135 (a radioactive-labeled experimental drug)
What this could lead to: If successful, this study will help researchers understand how SEP-380135 moves through the body, which is a necessary step toward developing a potential treatment for schizophrenia.
What could go wrong: This is a very early, small study in just 8 healthy men, not people with schizophrenia. It only measures drug processing, not whether the drug works or is safe long-term. The radioactive label is safe at these levels but adds a minor risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Celerion, Inc.

Lincoln, Nebraska, 68502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.